Veterinary Medicines

CORIPRAVAC

Authorised
  • Avibacterium paragallinarum, serotype A, strain 17756, Inactivated
  • Avibacterium paragallinarum, serotype B, strain 0222, Inactivated
  • Avibacterium paragallinarum, serotype C, strain Modesto, Inactivated
Download as PDF

Product identification

Medicine name:
CORIPRAVAC
Active substance:
  • Avibacterium paragallinarum, serotype A, strain 17756, Inactivated
  • Avibacterium paragallinarum, serotype B, strain 0222, Inactivated
  • Avibacterium paragallinarum, serotype C, strain Modesto, Inactivated
Target species:
  • Chicken (pullet for egg production, future layer)
  • Future breeder pullet
Route of administration:
  • Intramuscular use
  • Subcutaneous use

Product details

Active substance and strength:
  • Avibacterium paragallinarum, serotype A, strain 17756, Inactivated
    32.00
    Antibody microagglutination-lytic reaction
    /
    1.00
    Dose
  • Avibacterium paragallinarum, serotype B, strain 0222, Inactivated
    32.00
    Antibody microagglutination-lytic reaction
    /
    1.00
    Dose
  • Avibacterium paragallinarum, serotype C, strain Modesto, Inactivated
    32.00
    Antibody microagglutination-lytic reaction
    /
    1.00
    Dose
Pharmaceutical form:
  • Suspension for injection
Withdrawal period by route of administration:
  • Intramuscular use
    • Chicken (pullet for egg production, future layer)
      • Meat and offal
        0
        day
    • Future breeder pullet
      • Meat and offal
        0
        day
  • Subcutaneous use
    • Chicken (pullet for egg production, future layer)
      • Meat and offal
        0
        day
    • Future breeder pullet
      • Meat and offal
        0
        day
Anatomical therapeutic chemical veterinary (ATCvet) codes:
  • QI01AB04
Legal status of supply:
  • Veterinary medicinal product subject to veterinary prescription
Authorisation status:
  • Valid
Authorised in:
  • Spain
Package description:

Additional information

Entitlement type:
  • Marketing Authorisation
Legal basis of product authorisation:
  • Full application - Known active substance (Article 12(3) of Directive No 2001/82/EC)
Marketing authorisation holder:
  • Laboratorios Hipra S.A.
Marketing authorisation date:
Manufacturing sites for batch release:
  • Laboratorios Hipra S.A.
Responsible authority:
  • The Spanish Agency Of Medicines And Medical Devices
Authorisation number:
  • 2484 ESP
Date of authorisation status change:

Documents

Summary of Product Characteristics

This document does not exist in this language (English). You can find it in another language below.
Spanish (PDF)
Published on: 9/11/2022
Download

Package Leaflet

This document does not exist in this language (English). You can find it in another language below.
Spanish (PDF)
Published on: 9/11/2022
Download

Labelling

This document does not exist in this language (English). You can find it in another language below.
Spanish (PDF)
Published on: 9/11/2022
Download
How useful was this page?:
No votes yet
"Please do not include any personal data, such as your name or contact details. If you do, you consent to the processing of that data in accordance with EMA’s Privacy Statement concerning requests for information or access to documents. If you would like a reply from EMA, please Send a question to EMA instead."